Latest News and Press Releases

SALT LAKE CITY, April 20, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of preclinical data characterizing MPI-0486348, the lead compound in the...

SALT LAKE CITY, April 19, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with...

SALT LAKE CITY, April 12, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc (Nasdaq:MYRX) today announced that it has received a notice from Javelin Pharmaceuticals, Inc. (NYSE Amex:JAV) of its...

SALT LAKE CITY, March 15, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX), announced today that a registration statement on Form S-4 relating to the proposed merger with Javelin...

SALT LAKE CITY, Feb. 16, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its second fiscal quarter ended December 31, 2009. "We are pleased...

SALT LAKE CITY, Feb. 3, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today...

SALT LAKE CITY, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted Javelin Pharmaceuticals’...

Creates Pipeline With Potential Near-Term Product Launch of Dyloject(TM) and Portfolio of Early-, Mid- and Late-Stage Drug Candidates in Cancer, HIV and Pain ...

SALT LAKE CITY, Dec. 1, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the initiation of a Phase 2b study of MPC-4326, a first-in-class, small molecule inhibitor of...

SALT LAKE CITY, Nov. 23, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) announced today that Adrian Hobden, President and CEO, is scheduled to present an overview of the Company at...